In recent trading session, ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) saw 8,272,443 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $1.99 trading at $0.08 or 4.19% at recent trade assigns it a market valuation of $76.36 Million. That current trading price of ASLN’s stock is at a discount of -311.06% from its 52-week high price of $8.18 and is indicating a premium of 82.41% from its 52-week low price of $0.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 42.59 Million shares which gives us an average trading volume of 71.73 Million if we extend that period to 3-months.
For ASLAN Pharmaceuticals Limited (ASLN), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.3. Splitting up the data highlights that, out of 3 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.09 in the current quarter.
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) trade information
Upright in the green today for gaining 4.19%, in the last five days ASLN remained trading in the green while hitting it’s week-highest on Friday, Oct 16 when the stock touched $2.46 price level, adding 17.89% to its value on the day. ASLAN Pharmaceuticals Limited’s shares saw a change of -0.49% in year-to-date performance and have moved 4.12% in past 5-day. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) showed a performance of 33.77% in past 30-days. Number of shares sold short was 239.91 Million shares which calculate 3.34 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $5.5 to the stock, which implies a rise of 176.38% to its current value. Analysts have been projecting $5 as a low price target for the stock while placing it at a high target of $6. It follows that stock’s current price would jump +201.51% in reaching the projected high whereas dropping to the targeted low would mean a loss of 151.26% for stock’s current value.
ASLAN Pharmaceuticals Limited (ASLN) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -5.2% while estimates for its earnings growth in next 5 years are of 0%
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)’s Major holders
Insiders are in possession of 0% of company’s total shares while institution are holding 8.68% percent of that, with stock having share float percentage of 8.68%. Investors also watch the number of corporate investors in a company very closely, which is 16 institutions for ASLAN Pharmaceuticals Limited that are currently holding shares of the company. Temasek Holdings (Private) Limited is the top institutional holder at ASLN for having 1.42 Million shares of worth $2.84 Million. And as of June 29, 2020, it was holding 18.97% of the company’s outstanding shares.
The second largest institutional holder is Sio Capital Management, LLC, which was holding about 1.38 Million shares on June 29, 2020. The number of shares represents firm’s hold over 18.36% of outstanding shares, having a total worth of $2.75 Million.